Up-regulated Expression and Related Gene Regulatory Networks of ANLN Predict Poor Prognosis and Correlate with Immune Infiltration in Hepatocellular Carcinoma

preprint OA: closed
View at publisher

Abstract

Abstract Background: The aberrant Anillin (ANLN) expression is reported to be associated with carcinogenesis. In this study, sequencing data collected from the Cancer Genome Atlas database were utilized to analyze ANLN expression in hepatocellular carcinoma (HCC). Methods: The relationships of clinicopathological features with ANLN were investigated, and gene set enrichment analysis (GSEA) was performed to reveal the ANLN-related functions. LinkedOmics was employed to identify the co-expressed genes of ANLN and to examine the target networks of kinases, microRNAs (miRNAs) and transcription factors (TFs). Besides, the correlation of ANLN expression with cancer immune infiltrates was analyzed by TIMER. Results: ANLN over-expression predicted dismal prognosis, and GESA results revealed several functions that were related to cell cycle and mRNA binding. Moreover, functional network analysis indicated that, ANLN might regulate DNA replication and cell cycle signaling through pathways that involved several cancer-related kinases, miRNAs and E2F1. Additionally, ANLN was suggested to be associated with the infiltration of several immune cells, which was proved to be upregulated in both HCC cells and tissues. Conclusion: Those efficiently mined data reveal information regarding ANLN expression, the potential regulatory networks and the relationship with immune infiltration in HCC, which lay a foundation for further study on the role of ANLN in carcinogenesis.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00